A similar pattern was observed for RANKL protein expression which was detectable in 40.8% of tumors from BRCA WT patients, with intermediate or high expression in only 5.1% of breast cancer samples, but which was found in 59.1% of malignant tumors from BRCA1 germline mutation carriers with intermediate or high expression in 14.8% samples. This evidence concerns the gene TNFSF11 and breast cancer.